Global Peptide Drug Conjugates Market Size study & Forecast, by Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline Products) by Type (Therapeutic, Diagnostic) and Regional Analysis, 2022-2029
Global Peptide Drug Conjugates Market is valued at approximately USD 596.27 million in 2021 and is anticipated to grow with a healthy growth rate of more than 18.58% over the forecast period 2022-2029. Peptide–drug conjugates are organic molecules composed of a small drug molecule, a peptide, and a linker. The drug molecule is necessary for the biological activity aids in targeted administration and helps in the enhance the effectiveness of treatment and frequently minimizing undesirable side effects. The increasing expenditure on clinical trial, favorable reimbursement policies, coupled with the rising expenditure on the development of the healthcare facilities are the primary factors that are attributing towards the market growth around the world.
The rising incidences of cancer and related mortality is fueling the demand for peptide drug conjugates for the treatment of the target diseases. The National Cancer Institute, the number of cancer patients is projected to rise to 29.5 million cases by the year 2040 from 18.1 million cases in the year 2018. Accordingly, as per the National Cancer Institute, there are more than 250 FDA approved chemotherapeutic drugs used in the treatment of malignant tumors. Thus, these aforementioned factors are exhibiting a positive influence on the growth of the market. Moreover, a strong product pipeline, as well as the growing R&D investment are presenting various lucrative opportunities over the forecasting years. However, the slow clinical development process and major drawback associated with such small molecules are hindering the market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Peptide Drug Conjugates Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing awareness about availability of treatment options, along with the rising government initiatives and favorable reimbursement policies. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the increasing incidences of cancer and related mortality, as well as growing investments to develop and commercialize such novel delivery systems in the market space.
Major market players included in this report are:
Novartis AG
Oncopeptides AB
Bicycle Therapeutics
AstraZeneca
Cybrexa Therapeutics
Angiochem Inc.
Innovasium Soricimed Biopharma
Theratechnologies
Pfizer Inc.
Validus Pharmaceuticals LLC
Recent Developments in the Market:
In November 2022, Cybrexa Therapeutics and Exelixis, Inc. unveiled the company collaborative agreement to offer Exelixis the right to acquire, first-in-class peptide-drug conjugate (PDC), CBX-12. The main objective of this initiative is likely to expand its clinical pipeline for the targeted drug therapy.
In June 2019, Novartis AG and PeptiDream Inc. entered a strategic collaboration in order to develop PDC, macrocyclic peptide for diagnostic and therapeutic applications.
Global Peptide Drug Conjugates Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Type, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Lutetium
Melflufen
ANG1005
BT1718
CBX-12
Other Pipeline Products
By Type:
Therapeutic
Diagnostic
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
The rising incidences of cancer and related mortality is fueling the demand for peptide drug conjugates for the treatment of the target diseases. The National Cancer Institute, the number of cancer patients is projected to rise to 29.5 million cases by the year 2040 from 18.1 million cases in the year 2018. Accordingly, as per the National Cancer Institute, there are more than 250 FDA approved chemotherapeutic drugs used in the treatment of malignant tumors. Thus, these aforementioned factors are exhibiting a positive influence on the growth of the market. Moreover, a strong product pipeline, as well as the growing R&D investment are presenting various lucrative opportunities over the forecasting years. However, the slow clinical development process and major drawback associated with such small molecules are hindering the market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Peptide Drug Conjugates Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing awareness about availability of treatment options, along with the rising government initiatives and favorable reimbursement policies. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the increasing incidences of cancer and related mortality, as well as growing investments to develop and commercialize such novel delivery systems in the market space.
Major market players included in this report are:
Novartis AG
Oncopeptides AB
Bicycle Therapeutics
AstraZeneca
Cybrexa Therapeutics
Angiochem Inc.
Innovasium Soricimed Biopharma
Theratechnologies
Pfizer Inc.
Validus Pharmaceuticals LLC
Recent Developments in the Market:
In November 2022, Cybrexa Therapeutics and Exelixis, Inc. unveiled the company collaborative agreement to offer Exelixis the right to acquire, first-in-class peptide-drug conjugate (PDC), CBX-12. The main objective of this initiative is likely to expand its clinical pipeline for the targeted drug therapy.
In June 2019, Novartis AG and PeptiDream Inc. entered a strategic collaboration in order to develop PDC, macrocyclic peptide for diagnostic and therapeutic applications.
Global Peptide Drug Conjugates Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Type, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Lutetium
Melflufen
ANG1005
BT1718
CBX-12
Other Pipeline Products
By Type:
Therapeutic
Diagnostic
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
1.2.1. Peptide Drug Conjugates Market, by Region, 2019-2029 (USD Million)
1.2.2. Peptide Drug Conjugates Market, by Product, 2019-2029 (USD Million)
1.2.3. Peptide Drug Conjugates Market, by Type, 2019-2029 (USD Million)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL PEPTIDE DRUG CONJUGATES MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL PEPTIDE DRUG CONJUGATES MARKET DYNAMICS
3.1. Peptide Drug Conjugates Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising incidences of cancer and related mortality
3.1.1.2. Increasing expenditure on clinical trial
3.1.2. Market Challenges
3.1.2.1. Slow clinical development process
3.1.2.2. Major drawback associated with such small molecules
3.1.3. Market Opportunities
3.1.3.1. Strong product pipeline
3.1.3.2. Growing R&D investment
CHAPTER 4. GLOBAL PEPTIDE DRUG CONJUGATES MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. RISK ASSESSMENT: COVID-19 IMPACT
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
CHAPTER 6. GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY PRODUCT
6.1. Market Snapshot
6.2. Global Peptide Drug Conjugates Market by Product, Performance - Potential Analysis
6.3. Global Peptide Drug Conjugates Market Estimates & Forecasts by Product 2019-2029 (USD Million)
6.4. Peptide Drug Conjugates Market, Sub Segment Analysis
6.4.1. Lutetium
6.4.2. Melflufen
6.4.3. ANG1005
6.4.4. BT1718
6.4.5. CBX-12
6.4.6. Other Pipeline Products
CHAPTER 7. GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY TYPE
7.1. Market Snapshot
7.2. Global Peptide Drug Conjugates Market by Type, Performance - Potential Analysis
7.3. Global Peptide Drug Conjugates Market Estimates & Forecasts by Type 2019-2029 (USD Million)
7.4. Peptide Drug Conjugates Market, Sub Segment Analysis
7.4.1. Therapeutic
7.4.2. Diagnostic
CHAPTER 8. GLOBAL PEPTIDE DRUG CONJUGATES MARKET, REGIONAL ANALYSIS
8.1. Peptide Drug Conjugates Market, Regional Market Snapshot
8.2. North America Peptide Drug Conjugates Market
8.2.1. U.S. Peptide Drug Conjugates Market
8.2.1.1. Product breakdown estimates & forecasts, 2019-2029
8.2.1.2. Type breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Peptide Drug Conjugates Market
8.3. Europe Peptide Drug Conjugates Market Snapshot
8.3.1. U.K. Peptide Drug Conjugates Market
8.3.2. Germany Peptide Drug Conjugates Market
8.3.3. France Peptide Drug Conjugates Market
8.3.4. Spain Peptide Drug Conjugates Market
8.3.5. Italy Peptide Drug Conjugates Market
8.3.6. Rest of Europe Peptide Drug Conjugates Market
8.4. Asia-Pacific Peptide Drug Conjugates Market Snapshot
8.4.1. China Peptide Drug Conjugates Market
8.4.2. India Peptide Drug Conjugates Market
8.4.3. Japan Peptide Drug Conjugates Market
8.4.4. Australia Peptide Drug Conjugates Market
8.4.5. South Korea Peptide Drug Conjugates Market
8.4.6. Rest of Asia Pacific Peptide Drug Conjugates Market
8.5. Latin America Peptide Drug Conjugates Market Snapshot
8.5.1. Brazil Peptide Drug Conjugates Market
8.5.2. Mexico Peptide Drug Conjugates Market
8.5.3. Rest of Latin America Peptide Drug Conjugates Market
8.6. Rest of The World Peptide Drug Conjugates Market
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Novartis AG
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Oncopeptides AB
9.2.3. Bicycle Therapeutics
9.2.4. AstraZeneca
9.2.5. Cybrexa Therapeutics
9.2.6. Angiochem Inc.
9.2.7. Innovasium Soricimed Biopharma
9.2.8. Theratechnologies
9.2.9. Pfizer Inc.
9.2.10. Validus Pharmaceuticals LLC
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
1.2.1. Peptide Drug Conjugates Market, by Region, 2019-2029 (USD Million)
1.2.2. Peptide Drug Conjugates Market, by Product, 2019-2029 (USD Million)
1.2.3. Peptide Drug Conjugates Market, by Type, 2019-2029 (USD Million)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL PEPTIDE DRUG CONJUGATES MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL PEPTIDE DRUG CONJUGATES MARKET DYNAMICS
3.1. Peptide Drug Conjugates Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising incidences of cancer and related mortality
3.1.1.2. Increasing expenditure on clinical trial
3.1.2. Market Challenges
3.1.2.1. Slow clinical development process
3.1.2.2. Major drawback associated with such small molecules
3.1.3. Market Opportunities
3.1.3.1. Strong product pipeline
3.1.3.2. Growing R&D investment
CHAPTER 4. GLOBAL PEPTIDE DRUG CONJUGATES MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. RISK ASSESSMENT: COVID-19 IMPACT
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
CHAPTER 6. GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY PRODUCT
6.1. Market Snapshot
6.2. Global Peptide Drug Conjugates Market by Product, Performance - Potential Analysis
6.3. Global Peptide Drug Conjugates Market Estimates & Forecasts by Product 2019-2029 (USD Million)
6.4. Peptide Drug Conjugates Market, Sub Segment Analysis
6.4.1. Lutetium
6.4.2. Melflufen
6.4.3. ANG1005
6.4.4. BT1718
6.4.5. CBX-12
6.4.6. Other Pipeline Products
CHAPTER 7. GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY TYPE
7.1. Market Snapshot
7.2. Global Peptide Drug Conjugates Market by Type, Performance - Potential Analysis
7.3. Global Peptide Drug Conjugates Market Estimates & Forecasts by Type 2019-2029 (USD Million)
7.4. Peptide Drug Conjugates Market, Sub Segment Analysis
7.4.1. Therapeutic
7.4.2. Diagnostic
CHAPTER 8. GLOBAL PEPTIDE DRUG CONJUGATES MARKET, REGIONAL ANALYSIS
8.1. Peptide Drug Conjugates Market, Regional Market Snapshot
8.2. North America Peptide Drug Conjugates Market
8.2.1. U.S. Peptide Drug Conjugates Market
8.2.1.1. Product breakdown estimates & forecasts, 2019-2029
8.2.1.2. Type breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Peptide Drug Conjugates Market
8.3. Europe Peptide Drug Conjugates Market Snapshot
8.3.1. U.K. Peptide Drug Conjugates Market
8.3.2. Germany Peptide Drug Conjugates Market
8.3.3. France Peptide Drug Conjugates Market
8.3.4. Spain Peptide Drug Conjugates Market
8.3.5. Italy Peptide Drug Conjugates Market
8.3.6. Rest of Europe Peptide Drug Conjugates Market
8.4. Asia-Pacific Peptide Drug Conjugates Market Snapshot
8.4.1. China Peptide Drug Conjugates Market
8.4.2. India Peptide Drug Conjugates Market
8.4.3. Japan Peptide Drug Conjugates Market
8.4.4. Australia Peptide Drug Conjugates Market
8.4.5. South Korea Peptide Drug Conjugates Market
8.4.6. Rest of Asia Pacific Peptide Drug Conjugates Market
8.5. Latin America Peptide Drug Conjugates Market Snapshot
8.5.1. Brazil Peptide Drug Conjugates Market
8.5.2. Mexico Peptide Drug Conjugates Market
8.5.3. Rest of Latin America Peptide Drug Conjugates Market
8.6. Rest of The World Peptide Drug Conjugates Market
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Novartis AG
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Oncopeptides AB
9.2.3. Bicycle Therapeutics
9.2.4. AstraZeneca
9.2.5. Cybrexa Therapeutics
9.2.6. Angiochem Inc.
9.2.7. Innovasium Soricimed Biopharma
9.2.8. Theratechnologies
9.2.9. Pfizer Inc.
9.2.10. Validus Pharmaceuticals LLC
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
LIST OF TABLES
TABLE 1. Global Peptide Drug Conjugates Market, report scope
TABLE 2. Global Peptide Drug Conjugates Market estimates & forecasts by Region 2019-2029 (USD Million)
TABLE 3. Global Peptide Drug Conjugates Market estimates & forecasts by Product 2019-2029 (USD Million)
TABLE 4. Global Peptide Drug Conjugates Market estimates & forecasts by Type 2019-2029 (USD Million)
TABLE 5. Global Peptide Drug Conjugates Market by segment, estimates & forecasts, 2019-2029 (USD Million)
TABLE 6. Global Peptide Drug Conjugates Market by region, estimates & forecasts, 2019-2029 (USD Million)
TABLE 7. Global Peptide Drug Conjugates Market by segment, estimates & forecasts, 2019-2029 (USD Million)
TABLE 8. Global Peptide Drug Conjugates Market by region, estimates & forecasts, 2019-2029 (USD Million)
TABLE 9. Global Peptide Drug Conjugates Market by segment, estimates & forecasts, 2019-2029 (USD Million)
TABLE 10. Global Peptide Drug Conjugates Market by region, estimates & forecasts, 2019-2029 (USD Million)
TABLE 11. Global Peptide Drug Conjugates Market by segment, estimates & forecasts, 2019-2029 (USD Million)
TABLE 12. Global Peptide Drug Conjugates Market by region, estimates & forecasts, 2019-2029 (USD Million)
TABLE 13. Global Peptide Drug Conjugates Market by segment, estimates & forecasts, 2019-2029 (USD Million)
TABLE 14. Global Peptide Drug Conjugates Market by region, estimates & forecasts, 2019-2029 (USD Million)
TABLE 15. U.S. Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 16. U.S. Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 17. U.S. Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 18. Canada Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 19. Canada Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 20. Canada Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 21. UK Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 22. UK Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 23. UK Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 24. Germany Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 25. Germany Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 26. Germany Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 27. France Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 28. France Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 29. France Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 30. Italy Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 31. Italy Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 32. Italy Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 33. Spain Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 34. Spain Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 35. Spain Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 36. RoE Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 37. RoE Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 38. RoE Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 39. China Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 40. China Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 41. China Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 42. India Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 43. India Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 44. India Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 45. Japan Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 46. Japan Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 47. Japan Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 48. South Korea Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 49. South Korea Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 50. South Korea Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 51. Australia Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 52. Australia Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 53. Australia Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 54. RoAPAC Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 55. RoAPAC Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 56. RoAPAC Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 57. Brazil Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 58. Brazil Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 59. Brazil Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 60. Mexico Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 61. Mexico Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 62. Mexico Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 63. RoLA Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 64. RoLA Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 65. RoLA Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 66. Row Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 67. Row Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 68. Row Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 69. List of secondary sources, used in the study of global Peptide Drug Conjugates Market
TABLE 70. List of primary sources, used in the study of global Peptide Drug Conjugates Market
TABLE 71. Years considered for the study
TABLE 72. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
TABLE 1. Global Peptide Drug Conjugates Market, report scope
TABLE 2. Global Peptide Drug Conjugates Market estimates & forecasts by Region 2019-2029 (USD Million)
TABLE 3. Global Peptide Drug Conjugates Market estimates & forecasts by Product 2019-2029 (USD Million)
TABLE 4. Global Peptide Drug Conjugates Market estimates & forecasts by Type 2019-2029 (USD Million)
TABLE 5. Global Peptide Drug Conjugates Market by segment, estimates & forecasts, 2019-2029 (USD Million)
TABLE 6. Global Peptide Drug Conjugates Market by region, estimates & forecasts, 2019-2029 (USD Million)
TABLE 7. Global Peptide Drug Conjugates Market by segment, estimates & forecasts, 2019-2029 (USD Million)
TABLE 8. Global Peptide Drug Conjugates Market by region, estimates & forecasts, 2019-2029 (USD Million)
TABLE 9. Global Peptide Drug Conjugates Market by segment, estimates & forecasts, 2019-2029 (USD Million)
TABLE 10. Global Peptide Drug Conjugates Market by region, estimates & forecasts, 2019-2029 (USD Million)
TABLE 11. Global Peptide Drug Conjugates Market by segment, estimates & forecasts, 2019-2029 (USD Million)
TABLE 12. Global Peptide Drug Conjugates Market by region, estimates & forecasts, 2019-2029 (USD Million)
TABLE 13. Global Peptide Drug Conjugates Market by segment, estimates & forecasts, 2019-2029 (USD Million)
TABLE 14. Global Peptide Drug Conjugates Market by region, estimates & forecasts, 2019-2029 (USD Million)
TABLE 15. U.S. Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 16. U.S. Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 17. U.S. Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 18. Canada Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 19. Canada Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 20. Canada Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 21. UK Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 22. UK Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 23. UK Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 24. Germany Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 25. Germany Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 26. Germany Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 27. France Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 28. France Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 29. France Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 30. Italy Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 31. Italy Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 32. Italy Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 33. Spain Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 34. Spain Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 35. Spain Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 36. RoE Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 37. RoE Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 38. RoE Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 39. China Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 40. China Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 41. China Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 42. India Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 43. India Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 44. India Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 45. Japan Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 46. Japan Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 47. Japan Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 48. South Korea Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 49. South Korea Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 50. South Korea Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 51. Australia Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 52. Australia Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 53. Australia Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 54. RoAPAC Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 55. RoAPAC Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 56. RoAPAC Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 57. Brazil Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 58. Brazil Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 59. Brazil Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 60. Mexico Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 61. Mexico Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 62. Mexico Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 63. RoLA Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 64. RoLA Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 65. RoLA Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 66. Row Peptide Drug Conjugates Market estimates & forecasts, 2019-2029 (USD Million)
TABLE 67. Row Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 68. Row Peptide Drug Conjugates Market estimates & forecasts by segment 2019-2029 (USD Million)
TABLE 69. List of secondary sources, used in the study of global Peptide Drug Conjugates Market
TABLE 70. List of primary sources, used in the study of global Peptide Drug Conjugates Market
TABLE 71. Years considered for the study
TABLE 72. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
LIST OF FIGURES
FIG 1. Global Peptide Drug Conjugates Market, research methodology
FIG 2. Global Peptide Drug Conjugates Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Peptide Drug Conjugates Market, key trends 2021
FIG 5. Global Peptide Drug Conjugates Market, growth prospects 2022-2029
FIG 6. Global Peptide Drug Conjugates Market, porters 5 force model
FIG 7. Global Peptide Drug Conjugates Market, pest analysis
FIG 8. Global Peptide Drug Conjugates Market, value chain analysis
FIG 9. Global Peptide Drug Conjugates Market by segment, 2019 & 2029 (USD Million)
FIG 10. Global Peptide Drug Conjugates Market by segment, 2019 & 2029 (USD Million)
FIG 11. Global Peptide Drug Conjugates Market by segment, 2019 & 2029 (USD Million)
FIG 12. Global Peptide Drug Conjugates Market by segment, 2019 & 2029 (USD Million)
FIG 13. Global Peptide Drug Conjugates Market by segment, 2019 & 2029 (USD Million)
FIG 14. Global Peptide Drug Conjugates Market, regional snapshot 2019 & 2029
FIG 15. North America Peptide Drug Conjugates Market 2019 & 2029 (USD Million)
FIG 16. Europe Peptide Drug Conjugates Market 2019 & 2029 (USD Million)
FIG 17. Asia pacific Peptide Drug Conjugates Market 2019 & 2029 (USD Million)
FIG 18. Latin America Peptide Drug Conjugates Market 2019 & 2029 (USD Million)
FIG 19. Global Peptide Drug Conjugates Market, company Market share analysis (2021)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
FIG 1. Global Peptide Drug Conjugates Market, research methodology
FIG 2. Global Peptide Drug Conjugates Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Peptide Drug Conjugates Market, key trends 2021
FIG 5. Global Peptide Drug Conjugates Market, growth prospects 2022-2029
FIG 6. Global Peptide Drug Conjugates Market, porters 5 force model
FIG 7. Global Peptide Drug Conjugates Market, pest analysis
FIG 8. Global Peptide Drug Conjugates Market, value chain analysis
FIG 9. Global Peptide Drug Conjugates Market by segment, 2019 & 2029 (USD Million)
FIG 10. Global Peptide Drug Conjugates Market by segment, 2019 & 2029 (USD Million)
FIG 11. Global Peptide Drug Conjugates Market by segment, 2019 & 2029 (USD Million)
FIG 12. Global Peptide Drug Conjugates Market by segment, 2019 & 2029 (USD Million)
FIG 13. Global Peptide Drug Conjugates Market by segment, 2019 & 2029 (USD Million)
FIG 14. Global Peptide Drug Conjugates Market, regional snapshot 2019 & 2029
FIG 15. North America Peptide Drug Conjugates Market 2019 & 2029 (USD Million)
FIG 16. Europe Peptide Drug Conjugates Market 2019 & 2029 (USD Million)
FIG 17. Asia pacific Peptide Drug Conjugates Market 2019 & 2029 (USD Million)
FIG 18. Latin America Peptide Drug Conjugates Market 2019 & 2029 (USD Million)
FIG 19. Global Peptide Drug Conjugates Market, company Market share analysis (2021)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
